Trandolapril/verapamil

Trandolapril/verapamil
Combination of
TrandolaprilCalcium channel blocker
VerapamilACE inhibitor
Clinical data
Trade namesTarka
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Trandolapril/verapamil (Tarka)[2] is an oral antihypertensive medication that combines a slow release formulation of verapamil hydrochloride, a calcium channel blocker, and an immediate release formulation of trandolapril, an ACE inhibitor. The patent, held by Abbott Laboratories, expired on February 24, 2015.

This combination medication contains angiotensin-converting enzyme (ACE) inhibitor and calcium channel blocker and is prescribed for high blood pressure.[3][4][5]

References

  1. ^ "Active substance(s): trandolapril / verapamil" (PDF). List of nationally authorised medicinal products. European Medicines Agency. 29 October 2020.
  2. ^ "Tarka". drugs.com.
  3. ^ Reynolds NA, Wagstaff AJ, Keam SJ (2005). "Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension". Drugs. 65 (13): 1893–1914. doi:10.2165/00003495-200565130-00011. PMID 16114984. S2CID 46962760.
  4. ^ García Donaire JA, Ruilope LM (2007). "Trandolapril/verapamil combination in hypertensive diabetic patients". Vascular Health and Risk Management. 3 (1): 77–82. PMC 1994049. PMID 17583177.
  5. ^ Sharma SK, Ruggenenti P, Remuzzi G (2007). "Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination". Vascular Health and Risk Management. 3 (4): 453–465. PMC 2291330. PMID 17969376.


Stub icon

This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.